Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Daré Bioscience (DARE) has provided an update.
Daré Bioscience, Inc. has announced it is back in line with Nasdaq’s continued listing requirements after maintaining a minimum bid price of $1.00 per share for over ten consecutive trading sessions. This success marks the closure of previous compliance concerns with Nasdaq. Additionally, Daré is advancing towards Phase 3 studies of its Sildenafil Cream for treating female sexual arousal disorder, a condition with no FDA-approved treatments to date, while awaiting further FDA guidance on study endpoints and data requirements for a future new drug application.
Learn more about DARE stock on TipRanks’ Stock Analysis page.